FDAnews Device Daily Bulletin

ALCON PRESENTS NEW CLINICAL DATA AND PROVIDES REGULATORY UPDATE ON PATANASE NASAL SPRAY

Nov. 8, 2005
A A

An onset of action study shows faster allergy symptom relief with Alcon's olopatadine hydrochloride nasal spray 665 mcg (proposed brand name Patanase) when compared to mometasone furoate monohydrate nasal spray 50mcg (brand name Nasonex) for the treatment of seasonal allergic rhinitis. The study, presented today at the annual meeting of the American College of Allergy, Asthma & Immunology, also demonstrated that Patanase nasal spray has a rapid onset of action, as early as 30 minutes.
Yahoo News